Simplified urine-based method to detect rifampin underexposure in adults with tuberculosis: a prospective diagnostic accuracy study.
Yingda L Xie, Nisha Modi, Deborah Handler...
https://pubmed.ncbi.nlm.nih.gov/37877727/Actively Recruiting
Led by University of Virginia · Updated on 2026-01-27
200
Participants Needed
1
Research Sites
22 weeks
Total Duration
Researchers are studying how individual differences in how the body processes rifampin, a key tuberculosis TB drug, affect treatment success in children and adults with drug-sensitive pulmonary TB in Tanzania. The study focuses on using urine tests to measure rifampin levels as a simpler alternative to blood tests, aiming to adjust doses for better treatment outcomes. The trial also examines how gut infections may impact drug absorption and treatment response. Participants receive standard TB therapy with isoniazid, rifampin, pyrazinamide, and ethambutol. They are randomly assigned to two groups one with urine testing and possible rifampin dose adjustment at Day 14, and the other at Day 21. Urine spectrophotometry measures rifampin levels to guide dose increases if below target, with repeat testing and blood samples collected to confirm drug levels. Stool samples are also collected to study gut infections and their effect on rifampin. During the study, participants undergo urine and blood testing for rifampin levels, stool analysis, and clinical assessments including weight and sputum culture tests to monitor treatment progress. Safety is closely tracked through adverse event reports and blood tests for liver, kidney, and blood health. The main outcomes measured are rifampin levels in the blood at 21 days and any severe side effects within 56 days, with secondary outcomes tracking time to negative sputum cultures, weight changes, and intestinal health markers.
CONDITIONS
Precision Rifampin Trial for Personalized Dosing
S
Scott Heysell, MD, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Virginia
Lead Sponsor
Rutgers University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days
Participants undergo urine spectrophotometry testing and serum collection to measure rifampin levels. Stool samples are collected at regular intervals to evaluate enteropathogen burden and its effect on rifampin absorption and serum exposure.
Visits at Days 14, 21, and 28
Duration - Up to 56 days
Participants receive conventional weight-based tuberculosis therapy with possible rifampin dose adjustment based on urine spectrophotometry results at Day 14 or Day 21. Dose adjustments may continue through Day 56.
Visits up to Day 56 for dose adjustment and monitoring
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yingda L Xie, Nisha Modi, Deborah Handler...
https://pubmed.ncbi.nlm.nih.gov/37877727/Tania A Thomas, Saning'o Lukumay, Sijia Yu...
https://pubmed.ncbi.nlm.nih.gov/37171408/University of Virginia
Lead Sponsor
Rutgers University
Collaborating Sponsor